Maarten Cozijnsen

29 Chapter 1 General introduction 56. Billiet T, Papamichael K, de Bruyn M, et al. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn’s Disease. J Crohns Colitis 2015;9:1120-1126. 57. Vermeire S, Van Assche G, Rutgeerts P. Role of genetics in prediction of disease course and response to therapy. World J Gastroenterol 2010;16:2609-2615. 58. Repnik K, Koder S, Skok P, et al. Transferrin Level Before Treatment and Genetic Polymorphism in HFE Gene as Predictive Markers for Response to Adalimumab in Crohn’s Disease Patients. Biochem Genet 2016;54:476-486. 59. Barber GE, Yajnik V, Khalili H, et al. Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn’s Disease. Am J Gastroenterol 2016;111:1816- 1822. 60. West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med 2017;23:579-589. 61. Atreya R, Neumann H, Neufert C, et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med February 2014. 62. af Bjorkesten CG, Nieminen U, Sipponen T, et al. Mucosal healing at 3 months predicts long- term endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scand J Gastroenterol 2013;48:543-551. 63. Boschetti G, Garnero P, Moussata D, et al. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn’s disease. Inflamm Bowel Dis 2015;21:331-336. 64. Ripolles T, Paredes JM, Martinez-Perez MJ, et al. Ultrasonographic Changes at 12 Weeks of Anti- TNF Drugs Predict 1-year Sonographic Response and Clinical Outcome in Crohn’s Disease: A Multicenter Study. Inflamm Bowel Dis 2016;22:2465-2473. 65. Buisson A, Hordonneau C, Goutte M, et al. Diffusion-weighted magnetic resonance enterocolonography in predicting remission after anti-TNF induction therapy in Crohn’s disease. Dig Liver Dis 2016;48:260-266. 66. Naganuma M, Okuda S, Hisamatsu T, et al. Findings of ulceration and severe stricture on MRE can predict prognosis of Crohn’s disease in patients treated with anti-TNF treatment. Abdom Radiol NY 2017;42:141-151. 67. Stein R, Lee D, Leonard MB, et al. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn’s Disease. Inflamm Bowel Dis 2016;22:1370- 1377. 68. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3:47-91. 69. Veereman-Wauters G, de Ridder L, Veres G, et al. Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary. J Pediatr Gastroenterol Nutr 2012;54:830-837. 70. de Ridder L, Turner D, Wilson DC, et al. Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the porto pediatric IBD group. Inflamm Bowel Dis 2014;20:291-300. 71. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti- tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-881.